Colorectal Cancer
Chapters
1 Information about this Guideline
2 Introduction
3 Prevention Asymptomatic Population
4 Screening Asymptomatic Population
5 Risk Groups
6 Endoscopy: Performance and Polyp management
7 Pre-operative Diagnostics and Surgery
8 Adjuvant and Neoadjuvant Therapy
9 Management of Patients with Metastases and in the Palliative Situation
10 Follow-up Care
11 Quality Indicators
12 Abbildungsverzeichnis
13 Tabellenverzeichnis
14 Literaturverzeichnis
Search guideline
Recommendations
PDF
More
Cover
Recommendations
Settings
All guidelines
Chapters
1 Information about this Guideline
2 Introduction
3 Prevention Asymptomatic Population
4 Screening Asymptomatic Population
5 Risk Groups
6 Endoscopy: Performance and Polyp management
7 Pre-operative Diagnostics and Surgery
8 Adjuvant and Neoadjuvant Therapy
9 Management of Patients with Metastases and in the Palliative Situation
10 Follow-up Care
11 Quality Indicators
12 Abbildungsverzeichnis
13 Tabellenverzeichnis
14 Literaturverzeichnis
Search guideline
Cover
Recommendations
Settings
All guidelines
13
Tabellenverzeichnis
1
Table 1
Beteiligte Fachgesellschaften und Organisationen
Open table
2
Table 2
Arbeitsgruppen
Open table
3
Table 3
Recommended Screening Programs for HNPCC
Open table
4
Table 4
Classification Duodenal Polyposis Characteristics According to the Spigelman- Classification (modified according to [309])
Open table
5
Table 5
Overview of Guideline-Based Specific Procedural Quality Indicators of Colonoscopy
Open table
6
Table 6
Follow-Up Intervals After Polypectomy
Open table
7
Table 7
Staging of Colorectal Cancer
Open table
8
Table 8
Randomised Studies on First-Line Therapy With FOLFOXIRI In Unselected Patients
Open table
9
Table 9
Randomised Studies on First-Line Therapy With anti-EGFR Substances in RAS-wt Patients
Open table
10
Table 10
Summary of Meta-Analyses on Anti-EGFR Substances - OS
Open table
11
Table 11
Summary of Meta-Analyses on Anti-EGFR Substances - PFS
Open table
12
Table 12
Randomised Studies on First-Line Therapy With Bevacizumab In Unselected Patients
Open table
13
Table 13
Summary of Meta-Analyses On Bevacizumab - OS
Open table
14
Table 14
Summary of Meta-Analyses On Bevacizumab - PFS
Open table
15
Table 15
Randomised Studies on Second-Line Therapy With Anti-VEGF Substances
Open table
16
Table 16
Randomised Studies on Second-Line Therapy With Anti-EGFR Substances
Open table
17
Table 17
Programmed Examination for the Follow-Up of CRC UICC II or III
Open table
← Abbildungsverzeichnis
Literaturverzeichnis →
Open interactive reader